Status:
TERMINATED
Lamictal TM, Haloperidol Decanoate in Schizophrenia
Lead Sponsor:
Central Mental Clinic for Outpatients of Baku City
Conditions:
Schizophrenia
Eligibility:
All Genders
18-60 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to determine the effect of lamotrigine augmentation of Haloperidol decanoate in the treatment of Resistant Schizophrenia predominantly by verbal resistant hallucinosis: A ...
Detailed Description
METHOD:A structured clinical interview, for DSM-IV Axis I Disorder, Patient Edition, was used to diagnose schizophrenia according to DSM-IV. Three hundred fifty patients were studied. The patients wer...
Eligibility Criteria
Inclusion
Exclusion
- Display an acute systemic medical disorder or a medical disorder requiring frequent changes in medication;
- Display a history of seizures, cerebrovascular disease, structural brain damage, from trauma, focal neurological sings on examination, or evidence of any progressive neurological disorder, substance dependence (except tobacco).
- Inclusion Criteria:
- age from 18-60;
- both gender;
- resistant scizophrenia patients;
- previous treatment history;
- verbal resistant hallucinosis.
Key Trial Info
Start Date :
January 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2007
Estimated Enrollment :
335 Patients enrolled
Trial Details
Trial ID
NCT00947375
Start Date
January 1 2005
End Date
January 1 2007
Last Update
July 28 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Central Mental Clinic for Outpatients of Baku City
Baku, Azerbaijan, AZ0010